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Abstract 
Background: Macroglossia due to amyloid depositions can cause cosmetic problems and 
functional disability, and can lead to life-threatening airway obstruction. Management of 
macroglossia in systemic amyloidosis is controversial, and the role of surgery is unclear.  
Case Description: We present a case of a 66-year-old woman affected by macroglossia 
due to light chain amyloidosis who presented with eating and breathing difficulties. 
Because of prior successful results of radiotherapy for localized amyloid disease, our 
patient was treated with external beam radiation therapy (20 Gy in 10 fractions). The 
treatment was well tolerated by the patient. However, her systemic amyloidosis 
progressed, with a subclinical increase in tongue width.  
Conclusions: This is the first reported use of radiotherapy for amyloidosis of the tongue. 
There was no evidence of benefit using a total dose of 20 Gy. This therapeutic modality is 
not recommended for the routine management of macroglossia. 
 
Introduction 
Amyloidosis is a group of disorders characterized by extracellular deposition of 
insoluble amyloid fibrils within tissues. This deposition of amyloid can be either localized 
or systemic. The most common form of systemic disease is light chain (AL) amyloidosis, 
which results from the deposition of monoclonal immunoglobulin light chains. 
Amyloid involvement of the tongue is almost always secondary to systemic AL 
amyloidosis and can occur in up to 40% of cases [1–5]. Serious respiratory, eating and 
speech problems can be caused by a lingual involvement. Treatment of this condition is 
controversial and challenging. Case Rep Oncol 2011;4:392–399 
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We present a case of an elderly woman suffering from systemic AL amyloidosis with 
severe macroglossia. To our knowledge, this is the first case report that describes the use 
of external beam radiation therapy (EBRT) as treatment for macroglossia due to 
amyloidosis. 
Case Report 
A 66-year-old woman was seen in our radiation oncology department for symptomatic progressive 
macroglossia 7 years after her initial diagnosis of amyloidosis. The patient was a non-smoker, non-
drinker and had no significant family history. Her past medical history was notable for a hepatitis A 
infection and a latent tuberculosis infection treated with isoniazid. Her past surgical history included a 
hysterectomy and a bilateral ovariectomy. She also underwent simultaneous bilateral carpal tunnel 
surgery twice (between 1998 and 2001) before the diagnosis of systemic AL amyloidosis was made after 
two successive positive tongue biopsies. Amyloid deposits were also identified on bone marrow 
examination and were present in bone as well as in articular tissues of both shoulders, as suggested by 
magnetic resonance imaging. Further tests revealed a bone marrow plasmacytosis of between 5 and 
10%, a small decrease in serum gamma globulins and a kappa light chain band on serum 
immunofixation. 
The patient was initially treated with autologous stem cell transplantation (SCT), but her response to 
treatment was limited. Approximately 1 year later, she complained of dyspnea and developed 
obstructive sleep apnea requiring nasal continuous positive airway pressure (CPAP). Her respiratory 
symptoms were primarily related to the progressive macroglossia. The patient was later hospitalized for 
mild pulmonary hypertension and right heart failure. Besides sleep apnea, other possible explanations 
for the development of pulmonary hypertension included cardiac amyloidosis, although not all criteria 
for cardiac amyloid were met. The patient also received a pacemaker implant for sinus node 
dysfunction. 
A variety of systemic treatment regimens were used to control the progression of her disease 
following SCT. Medications given included etanercept and thalidomide; however, no response could be 
obtained. Unfortunately, after receiving thalidomide, the patient developed bilateral deep vein 
thrombosis, and a combination of oral melphalan and dexamethasone was prescribed for 2 years until 
the patient developed an osteoporotic vertebral compression fracture. 
In January 2009, the patient presented again with progressive macroglossia causing speech, 
mastication, swallowing and breathing difficulties. She experienced upper dysphagia when swallowing 
some solids, such as rice and pills. She also reported a grade 2 dyspnea and was still using her CPAP for 
sleep apnea. Physical examination revealed an oral opening of <4 cm and a markedly enlarged tongue, 
from its base to its tip, with a maximum tongue width of 6 cm. Indentations caused by her teeth were 
also present on the tongue (fig. 1). Except for a significant submandibular gland enlargement, the rest of 
the physical examination was within normal limits. 
Since the patient had already received several different treatments, further therapeutic options were 
explored for the management of her macroglossia. Surgery was excluded due to her cardiopulmonary 
comorbidities. After review of the literature, we proposed using EBRT as palliative therapy for her 
macroglossia (fig. 2) because of its documented success in the treatment of the localized form of 
amyloidosis. A total dose of 20 Gy was delivered in 10 fractions using a 6-MV linear accelerator. 
Treatment was given 5 days a week at 2 Gy per fraction, over a period of 14 days. Before the first 
treatment, the patient was evaluated by a cardiologist due to her pacemaker status. During treatment, 
telemetry monitoring and an appropriate shielding block were used to prevent pacemaker dysfunction. 
The patient was followed up at 1-month intervals for the first 3 months after radiotherapy, and then 
every 2–4 months. The primary aim of this study was to assess the tongue size. The secondary end point 
was the evaluation of the symptomatic response, respiratory and deglutition functions, mouth opening 
and side effects. 
After radiotherapy, the patient developed acute grade 1 stomatitis at the base and dorsum of the 
tongue, grade 2 stomatitis on the indented lateral margins of the tongue, grade 1 dysgeusia and grade 2 
pain, according to the National Cancer Institute Common Terminology Criteria for Adverse Events Case Rep Oncol 2011;4:392–399 
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(NCI CTCAE, version 3.0). No radiation-induced mucositis was observed on her cheeks or palate, and 
no upper respiratory toxicity occurred. A slight improvement in her sleep apnea and a reduction in 
CPAP from 15 to 12 cm H2O were observed. Unfortunately, the systemic amyloidosis subsequently 
progressed. The patient presented with subcutaneous amyloid nodules, increased arthralgia and general 
deterioration. At the 8-month follow-up, her tongue width was 7 cm while the tongue indentations 
appeared unchanged. Mouth opening, eating ability as well as speech and respiratory symptoms 
remained stable. No late toxicity was observed. At the 10-month follow-up, our patient reported a 
subjective clinical amelioration of her macroglossia, even though no significant amelioration of 
objective signs could be observed. The patient later experienced progression of systemic amyloidosis, 
severe heart failure and loss of autonomy. She died of multilobar pneumonia after 14 months of 
follow-up.  
Discussion 
Amyloidosis is a generic term for a heterogeneous group of diseases associated with 
extracellular tissue deposits of fibril proteins sharing a similar structure. Classically, 
identification of amyloid deposits is based on the presence of an apple-green 
birefringence under polarized light microscopy after staining with Congo red dye. There 
are several forms of amyloidosis, and its modern classification depends on the nature of 
the protein precursor of the amyloid fibrils. To date, 25 different human protein 
precursors have been identified [6]. The amyloid protein AL is derived from monoclonal 
lambda or kappa immunoglobulin light chains, the commonest form of clinical 
amyloidosis in developed countries [2, 5, 7]. Distribution of AL amyloid deposits can be 
systemic or, more rarely, restricted to one organ or tissue. The reported incidence of 
systemic AL amyloidosis, previously known as primary amyloidosis, is 8 per million 
patients per year [3, 5]. This systemic disorder coexists with multiple myeloma in 
approximately 10% of cases. 
Amyloidosis affecting the head and neck is rare, and most cases have the AL type of 
amyloid [5, 6]. Any site may be involved; however, the most common sites are the larynx 
and the tongue. Amyloidosis of the head and neck usually presents as a localized lesion, 
except in cases with an involvement of the tongue, which is typically secondary to the 
systemic disease [3, 5, 8–10]. Tongue involvement manifests as a firm to rubbery 
macroglossia; less frequently, it presents as a yellowish nodule or a raised white lesion [8]. 
Some authors consider macroglossia as a paraneoplastic manifestation of plasma cell 
dyscrasia which is virtually diagnostic of AL amyloidosis when associated with dominant 
organ dysfunction [2, 8]. Submandibular gland enlargement also frequently presents with 
macroglossia in AL amyloidosis [8, 11]. 
Macroglossia eventually causes cosmetic and functional problems. Speech impairment, 
mastication and swallowing problems, breathing and sleeping difficulties as well as life-
threatening complications such as airway obstruction may occur. Management of 
macroglossia depends primarily on the extent of organ involvement, on whether 
amyloidosis is localized or systemic, and on the amyloid protein type (different therapies 
exist for different types of amyloid) [7]. 
While it is well accepted that the localized form of lingual amyloidosis can be 
reasonably treated with surgery [2, 9, 12, 13], no established treatment exists for the 
management of macroglossia due to systemic amyloidosis. Cases reported in the literature 
are rare, and scientific evidence is lacking. The treatment options, gathered from Case Rep Oncol 2011;4:392–399 
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published French- and English-language articles, can be classified into systemic therapy, 
surgical intervention and surgical bypass measures. 
The current treatment for systemic AL disease is based on a systemic therapy which 
aims to suppress the plasma cell clone producing the amyloidogenic immunoglobulin 
light chain component. Standard treatment consists of high-dose melphalan and 
autologous SCT for selected patients, or a combination of melphalan and dexamethasone 
[14–16]. However, two-thirds of newly diagnosed patients are not eligible for SCT [7], 
and chemotherapy administration may be limited by the patient’s inability to tolerate the 
side effects, especially in older patients. Despite recent advances, the hematologic 
response to systemic therapy is still often incomplete, delayed or absent. Furthermore, 
organ damage such as macroglossia may be irreversible in spite of a hematologic 
response. Supportive care is thus essential to preserve function and maintain the patient’s 
quality of life [2, 5, 17]. 
As local therapy for macroglossia, the role of surgery remains unclear because of the 
poor long-term prognosis and the morbidity associated with the surgical procedure. 
Contraindications to surgical treatment include difficult intubation, abnormal bleeding 
tendency and difficulty in suturing and wound healing due to amyloidosis. Moreover, 
recurrence of amyloid depositions is frequent. Therefore, tracheostomy and gastrostomy 
or jejunostomy for enteral alimentation are the only approaches available for the majority 
of patients affected by systemic amyloidosis [1, 5]. 
The role of radiation therapy in the management of macroglossia secondary to amyloid 
has not been reported. To our knowledge, this is the first published case report on this 
treatment. 
The rationale behind the use of EBRT is its effect on the clonal plasma cells responsible 
for producing the light chains and amyloid fibrils [18, 19]. Plasma cells are radiosensitive 
and their response to radiotherapy has been demonstrated in multiple myeloma and 
plasmocytoma [20]. In addition, successful results have been obtained with EBRT for the 
radical or postoperative therapy of tracheobronchial amyloidosis [18, 20–24], localized 
laryngeal amyloidosis [25] and localized periocular or orbital amyloidosis [19, 26–28]. 
However, this therapy of the localized form of the disease has been questioned by some 
scientists due to the scarcity of plasma cells in a number of localized cases, especially in 
tracheobronchial amyloidosis. In localized amyloidosis, a clone of plasma cells is usually 
present at the site of amyloid deposition and has been implicated in the synthesis of large 
amounts of amyloid precursors [18]. Nevertheless, other researchers believe that 
radiotherapy operates via other mechanisms including its effect on local vasculature 
versus an induction of an immune response [20]. 
In their series, Neben-Wittich et al. [20] presented 7 consecutive patients treated with 
radical EBRT for tracheobronchial AL amyloidosis. All patients showed a favorable 
response to treatment, with improvement or stabilization of their symptoms. For upper 
and lower respiratory tract involvement, Gallivan and Gallivan [25] reported that 8 
patients out of 10 affected by laryngeal or tracheobronchial amyloid deposition achieved 
stabilization of their disease with 20 Gy. 
More recently, Oluk and Murphy [29] noted a significant regression of nasal and 
nasopharyngeal amyloidosis with the use of radiotherapy in a patient affected by AL 
amyloidosis associated with multiple myeloma. Improvement in symptoms also occurred. Case Rep Oncol 2011;4:392–399 
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The current case is the first reported use of radiotherapy as treatment for macroglossia 
due to systemic AL amyloidosis. Overall, EBRT was well tolerated but failed to provide 
significant palliation of symptoms. Furthermore, a slight increase in tongue width 
occurred after radiation therapy. 
If progression of amyloidosis is considered as the most probable cause of macroglossia 
deterioration in our patient, we must assess the efficacy of the administered treatment 
with regard to the dose-response relationship. An insufficient dose may explain the failure 
of radiotherapy in our case because we favored a safer dose administration in an attempt 
to prevent edema formation. Thus, only 20 Gy were given. In comparison, in the reported 
literature, doses of 30–34 Gy have been delivered for localized orbital amyloidosis [26, 28] 
and doses of 20–24 Gy for tracheobronchial amyloidosis [20, 24, 30]. Our treatment using 
20 Gy may have been insufficient for a case with tongue involvement. On the other hand, 
failure of EBRT in our patient may be partially explained by the progression of her 
systemic amyloidosis. 
Alternatively, if we entertain the notion that the increase in tongue width was 
secondary to a radiation-induced side effect, it would be reasonable to expect resolution 
of hyperemia and edema over time, as well as progressive fibrosis and atrophy. However, 
these changes were not observed in our patient after 14 months of follow-up. 
Although EBRT has been shown to be effective in the treatment of specific forms of 
amyloidosis involving the respiratory tract and head and neck, our clinical outcome does 
not support the use of EBRT for macroglossia in patients with AL amyloidosis. It is 
important to consider factors such as evolution of systemic amyloidosis, previous 
treatment received, comorbidities, airway and swallowing status, patient preference and 
dose of EBRT delivered. Also, it is essential to analyze dose-response relationships for 
efficacy and safety. Because there are relatively few systemic AL amyloidosis patients with 
severe macroglossia and because of the multitude of factors to consider, it would be 
difficult to perform randomized trials in this setting. Accordingly, all case reports are 
important in order to define the best therapeutic strategy for these patients. 
Conclusions 
Radiation therapy is not recommended for the standard management of macroglossia 
due to systemic AL amyloidosis. There was no evidence of a therapeutic benefit with 20-
Gy irradiation on a short-term basis. 
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Fig. 1. Oral examination reveals enlargement of the tongue, scalloping at the edge of the tongue and 
deep indentations adjacent to the premolars and molars. Due to the constant lingual pressure exerted by 
the teeth, the patient experienced oral discomfort. 
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Fig. 2. Axial, sagittal and coronal sections demonstrate isodose distribution and target coverage for 
lingual amyloidosis. Clinical target volume (orange), planning target volume (green), parotid glands 
(yellow) and bone marrow (red) are delineated on CT images for radiation therapy treatment planning. 
A 5-field coaxial beam arrangement was used for treatment, consisting of 1 anterior-posterior and 4 
oblique fields. The planning target volume received a dose of 20 Gy in 10 fractions. 
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